Incidence of antiplatelet factor 4/heparin antibody induction in patients undergoing percutaneous coronary revascularization.
Am J Cardiol
; 95(6): 744-7, 2005 Mar 15.
Article
en En
| MEDLINE
| ID: mdl-15757601
ABSTRACT
The incidence of antiplatelet factor-4/heparin antibody formation in patients who receive contemporary doses of unfractionated heparin in the setting of percutaneous coronary revascularization is unknown. Also unknown is the ability of these antibodies to activate platelets or adversely affect clinical outcome in the absence of clinically recognized heparin-induced thrombocytopenia. To address these questions, we serially measured antiplatelet factor-4/heparin antibody levels and performed serotonin release assays in patients who underwent percutaneous coronary intervention. Correlations were then made across antibody induction, heparin exposure, and clinical outcome at 6 months.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Factor Plaquetario 4
/
Heparina
/
Angioplastia Coronaria con Balón
/
Enfermedad Coronaria
/
Angina de Pecho
/
Formación de Anticuerpos
/
Infarto del Miocardio
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am J Cardiol
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos